Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 36 Issue 6
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2018  >  36(6): 488-492

ZHANG Zhe, CAI Weimin. Research progress on the effect of UGT1A1 gene polymorphisms on drug metabolism and clinical efficacy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
Citation: ZHANG Zhe, CAI Weimin. Research progress on the effect of UGT1A1 gene polymorphisms on drug metabolism and clinical efficacy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
shu

Research progress on the effect of UGT1A1 gene polymorphisms on drug metabolism and clinical efficacy

doi: 10.3969/j.issn.1006-0111.2018.06.003

  • School of Pharmacy, Fudan University, Shanghai 201203, China

  • Received Date: 2018-07-17
  • Rev Recd Date: 2018-10-09
  • UGT1A1 is an important gene in the process of drug metabolism. With the development of pharmacogenomics,which have been found that the UGT1A1 gene polymorphisms is relevant to the level of metabolism, affect the occurrence,development and treatment of disease. As the study progressed, the substrates of UGT1A1 have constantly been extended, including bilirubin, estrogen, irinotecan and some other drugs with a number of studies. Research on the relationship between UGT1A1 gene polymorphisms and these substrates have showed that UGT1A1 gene polymorphisms play an important significance on the clinic diagnosis and treatment, prognostic judgments and drug side effects. The research progress of the role of UGT1A1 gene polymorphisms to drug metabolism and clinical effects were reviewed in this paper.
  • [1] 郭栋,庞良芳,周宏灏. UGT酶的遗传药理学研究进展[J]. 中国新药杂志,2011,20(13):1188-1193.
    [2] 李登,王潞. UGT1A1基因多态性与伊立替康致迟发性腹泻及治疗的研究进展[J]. 科技信息, 2014(3):271-272.
    [3] 韦小兰,骆子义,邬宇美,等. 利用多重实时荧光定量PCR技术检测新生儿高胆红素血症患者UGT1A1基因多态性研究[J]. 新发传染病电子杂志, 2017(1):18-21+39.
    [4] 田玉廷. UGT1A1基因多态性研究进展[J]. 实用癌症杂志, 2013, 28(3):324-326.
    [5] 侯慧轩. 亚洲人群晚期结直肠癌UGT1A1基因多态性与伊立替康相关毒性的meta分析[D]. 乌鲁木齐:新疆医科大学, 2016.
    [6] INNOCENTI F,VOKES EE,RATAIN MJ. Irinogenetics:what is the right star?[J]. J Clin Oncol, 2006, 24(15):2221-2224.
    [7] YANG Y,ZHOU M,HU M,et al. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity:a meta-analysis[J]. Asia-Pacific J Clin Oncol, 2018, 14(5):e479-e489.
    [8] FUKUDA M,OKUMURA M,IWAKIRI T,et al. Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer[J]. Thorac Cancer, 2018, 9(1):51-58.
    [9] MCLEOD HL,SARGENT DJ,MARSH S,et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer:results from North American gastrointestinal intergroup trial N9741[J]. J Clin Oncol, 2010, 28(20):3227-3233.
    [10] 衡雪源,车峰远,来向阳,等. 中国部分地区肿瘤患者UGT1A1*28和UGT1A1*6位点基因多态性分布的差异研究[J]. 2016, 19(30):3705-3710.
    [11] LI GY,DUAN JF,LI WJ,et al. DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients[J]. J Cancer Res Ther, 2016, 12(2):782-786.
    [12] 叶茂芳. UGT1A1基因多态性与伊立替康毒性和疗效相关性的回顾性研究[D]. 济南:山东大学, 2017.
    [13] 栾家杰,刘俊,汪琳,等. 安徽地区汉族人群肿瘤患者UGT1A1*6基因多态性分布的差异性研究[J]. 中国药理学通报, 2018, 34(6):857-862.
    [14] NAKAMURA Y,SODA H,OKA M,et al. Randomized phase Ⅱ trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer:association of UGT1A1*6 and UGT1A1*27 with severe neutropenia[J]. J Thorac Oncol, 2011, 6(1):121-127.
    [15] RADOI VE,URSU RI,POENARU E,et al. Frequency of the UGT1A1*28 polymorphism in a Romanian Cohort of Gilbert syndrome individuals[J]. J Gastrointestin Liver Dis, 2017, 26(1):25-28.
    [16] MAZUR-KOMINEK K,ROMANOWSKI T,BIELAWSKI K,et al. Association between uridin diphosphate glucuronosylotransferase 1A1(UGT1A1) gene polymorphism and neonatal hyperbilirubinemia.[J]. Acta Biochim Pol, 2017,64(2):351-356.
    [17] KUO S,YANG S,YOU S,et al. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer[J]. Oncotarget, 2017, 8(13):20925-20938.
    [18] ADEGOKE OJ,SHU XO,GAO YT,et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1(UGT1A1) and risk of breast cancer[J]. Breast Cancer Res Treat, 2004, 85(3):239-245.
    [19] 田玉廷. UGT1A1基因多态性与乳腺癌发病风险的关系[D]. 石家庄:河北医科大学,2013.
    [20] DEMING SL,ZHENG W,XU WH,et al. UGT1A1 genetic polymorphisms, endogenous estrogen exposure, soy food intake, and endometrial cancer risk[J]. Cancer Epidemiol Biomark Prev, 2008, 17(3):563-570.
    [21] YOKOTA M,HIRASAWA A,MAKITA K,et al. Polymorphisms of estrogen metabolism-related genes ESR1, UGT2B17, and UGT1A1 are not associated with osteoporosis in surgically menopausal Japanese women.[J]. Menop Rev, 2015, 14(3):161-167.
    [22] 段舟萍. UGT1A1*6及*28基因多态性对伊立替康毒副反应及疗效影响的研究[D]. 南昌:南昌大学, 2015.
    [23] IYER L,DAS S,JANISCH L,et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity[J]. Pharmacogenomics J, 2002, 2(1):43-47.
    [24] 张君孝,王晨亮,黄美近,等. UGT1A1基因多态性与转移性结直肠癌伊立替康化疗毒性及疗效的关系[J]. 中国病理生理杂志, 2012,28(5):823-828.
    [25] CHEN X,LIU L,GUO Z,et al. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with lung cancer:a meta-analysis[J]. Cancer Chemother Pharmacol, 2017, 79(6):1109-1117.
    [26] TAKANO M,SUGIYAMA T. UGT1A1 polymorphisms in cancer:impact on irinotecan treatment[J]. Pharmgenom Pers Med, 2017, 10:61-68.
    [27] LU CY,HUANG CW,WU IC,et al. Clinical implication of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI in the first-line setting[J]. Transl Oncol, 2015, 8(6):474-479.
    [28] TOFFOLI G,CECCHIN E,CORONA G,et al. The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2006, 24(19):3061-3068.
    [29] SCHULZ C,HEINEMANN V,SCHALHORN A,et al. UGT1A1 gene polymorphism:impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer[J]. World J Gastroenterol, 2009, 15(40):5058-5066.
    [30] XU CL,TANG XS,QU YL,et al. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer[J]. Cancer Chemother Pharmacol, 2016, 78(1):119-130.
    [31] LUSIN TT,MRHAR A,TRONTELJ J. UGT1A1*28 polymorphism influences glucuronidation of bazedoxifene[J]. Pharmazie, 2015, 70(2):94-96.
    [32] BINS S,LENTING A,EL BOUAZZAOUI S,et al. Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity[J]. Pharmacogenomics, 2016, 17(14):1483-1490.
    [33] YAGURA H,WATANABE D,ASHIDA M,et al. Correlation between UGT1A1 polymorphisms and raltegravir plasma trough concentrations in Japanese HIV-1-infected patients[J]. J Infect Chemother, 2015, 21(10):713-717.
    [34] de OLIVEIRA ALMEIDA VC,RIBEIRO DD,GOMES KB,et al. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis:a prospective cohort study[J]. Mol Diagn Ther, 2014, 18(6):675-683.
    [35] IGARASHI R,INOUE T,FUJIYAMA N,et al. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma[J]. Med Oncol, 2018, 35(4):51.
    [36] CHEN P,ZHU KW,ZHANG DY,et al. Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens[J]. J Transl Med, 2018, 16(1):197.
  • 加载中
通讯作者: 陈斌, [email protected]
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(3449) PDF downloads(1464) Cited by()

Related
Proportional views

Research progress on the effect of UGT1A1 gene polymorphisms on drug metabolism and clinical efficacy

doi: 10.3969/j.issn.1006-0111.2018.06.003
  • School of Pharmacy, Fudan University, Shanghai 201203, China
  • Received Date: 2018-07-17
  • Rev Recd Date: 2018-10-09

Abstract: UGT1A1 is an important gene in the process of drug metabolism. With the development of pharmacogenomics,which have been found that the UGT1A1 gene polymorphisms is relevant to the level of metabolism, affect the occurrence,development and treatment of disease. As the study progressed, the substrates of UGT1A1 have constantly been extended, including bilirubin, estrogen, irinotecan and some other drugs with a number of studies. Research on the relationship between UGT1A1 gene polymorphisms and these substrates have showed that UGT1A1 gene polymorphisms play an important significance on the clinic diagnosis and treatment, prognostic judgments and drug side effects. The research progress of the role of UGT1A1 gene polymorphisms to drug metabolism and clinical effects were reviewed in this paper.

ZHANG Zhe, CAI Weimin. Research progress on the effect of UGT1A1 gene polymorphisms on drug metabolism and clinical efficacy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
Citation: ZHANG Zhe, CAI Weimin. Research progress on the effect of UGT1A1 gene polymorphisms on drug metabolism and clinical efficacy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
shu

    HTML

Reference (36)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return